With the Alexion Acquisition Set to Close This Quarter, Is AstraZeneca a Buy?
usx:azn usx:alxn Blog PostAlexion’s long-term prospects remain intact amid continued focus on rare diseases
usx:alxn Blog PostAstraZeneca's Acquisition of Alexion Is Nearly a Done Deal, But Is It a Good Deal?
usx:azn usx:alxn Blog Post